These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32452345)

  • 1. The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart.
    Perricone C; Conigliaro P; Ciccacci C; Marcucci E; Cafaro G; Bartoloni E; Perricone R; Novelli G; Borgiani P; Gerli R
    Clin Exp Rheumatol; 2020; 38(3):580. PubMed ID: 32452345
    [No Abstract]   [Full Text] [Related]  

  • 2. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma.
    Chaidos A; Katsarou A; Mustafa C; Milojkovic D; Karadimitris A
    Br J Haematol; 2020 Jul; 190(1):e9-e11. PubMed ID: 32369612
    [No Abstract]   [Full Text] [Related]  

  • 3. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.
    Allam SR; Dao A; Madhrira MM; Antiporta PB; Nair RR; Guiteau JJ; Reyad AI
    Transpl Infect Dis; 2020 Aug; 22(4):e13326. PubMed ID: 32406985
    [No Abstract]   [Full Text] [Related]  

  • 4. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.
    Michot JM; Albiges L; Chaput N; Saada V; Pommeret F; Griscelli F; Balleyguier C; Besse B; Marabelle A; Netzer F; Merad M; Robert C; Barlesi F; Gachot B; Stoclin A
    Ann Oncol; 2020 Jul; 31(7):961-964. PubMed ID: 32247642
    [No Abstract]   [Full Text] [Related]  

  • 5. How does COVID-19 kill? Uncertainty is hampering doctors' ability to choose treatments.
    Ledford H
    Nature; 2020 Apr; 580(7803):311-312. PubMed ID: 32273618
    [No Abstract]   [Full Text] [Related]  

  • 6. Lack of tocilizumab effect on mortality in COVID19 patients.
    Holt GE; Batra M; Murthi M; Kambali S; Santos K; Bastidas MVP; Asif H; Haddadi S; Arias S; Mirsaeidi M
    Sci Rep; 2020 Oct; 10(1):17100. PubMed ID: 33051534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine Storm Drugs Move from CAR T to COVID-19.
    Cancer Discov; 2020 Jul; 10(7):OF8. PubMed ID: 32371479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality.
    Smetana K; Rosel D; BrÁbek J
    In Vivo; 2020; 34(5):3027-3028. PubMed ID: 32871847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early tocilizumab treatment could improve survival among COVID-19 patients.
    Campins L; Boixeda R; Perez-Cordon L; Aranega R; Lopera C; Force L
    Clin Exp Rheumatol; 2020; 38(3):578. PubMed ID: 32456769
    [No Abstract]   [Full Text] [Related]  

  • 10. Tocilizumab in the treatment of a critical COVID-19 patient: a case report.
    Wang L; Peng X; Wang ZH; Cai J; Zhou FC
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5783-5787. PubMed ID: 32495916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.
    Loganathan S; Athalye SN; Joshi SR
    Expert Opin Biol Ther; 2020 Sep; 20(9):1025-1031. PubMed ID: 32700604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
    Zhang Y; Zhong Y; Pan L; Dong J
    Drug Discov Ther; 2020; 14(2):100-102. PubMed ID: 32378647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19: Stay Cool toward Corticosteroids.
    Fujishima S
    Keio J Med; 2020 Jun; 69(2):27-29. PubMed ID: 32475851
    [No Abstract]   [Full Text] [Related]  

  • 14. Kidney Transplantation and COVID-19.
    Merhi B; Gohh R
    R I Med J (2013); 2020 Sep; 103(8):34-37. PubMed ID: 32900010
    [No Abstract]   [Full Text] [Related]  

  • 15. Tocilizumab in COVID-19: Beware the risk of intestinal perforation.
    Vikse J; Henry BM
    Int J Antimicrob Agents; 2020 Jul; 56(1):106009. PubMed ID: 32389721
    [No Abstract]   [Full Text] [Related]  

  • 16. Vascular microthrombosis associated with increased interleukin-6. A severe acute respiratory distress syndrome in COVID-19 patients treated with tocilizumab.
    Mohebbi N; Abedini A; Lashgari R; Razavi F; Varahram M; Kiani A
    Adv Respir Med; 2020; 88(5):468-469. PubMed ID: 33169824
    [No Abstract]   [Full Text] [Related]  

  • 17. Lessons from the Italian COVID-19 frontline.
    Bellan M; Sainaghi PP; Gavelli F; Patrucco F; Avanzi GC; Pirisi M; Castello LM
    Minerva Med; 2020 Aug; 111(4):303-305. PubMed ID: 33032392
    [No Abstract]   [Full Text] [Related]  

  • 18. Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19.
    Ikonomidis I; Pavlidis G; Katsimbri P; Lambadiari V; Parissis J; Andreadou I; Tsoumani M; Boumpas D; Kouretas D; Iliodromitis E
    Food Chem Toxicol; 2020 Nov; 145():111694. PubMed ID: 32822775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients.
    Solis-García Del Pozo J; Galindo MF; Nava E; Jordán J
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7475-7484. PubMed ID: 32706087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19: Rescue by transcriptional inhibition.
    Shilatifard A
    Sci Adv; 2020 Jul; 6(27):. PubMed ID: 32937442
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.